Targeting complement activation in COVID-19

Blood. 2020 Oct 29;136(18):2000-2001. doi: 10.1182/blood.2020008925.

Abstract

In this issue of Blood, Yu et al have demonstrated that acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike proteins activate complement by engaging the alternative pathway (AP) and that blocking this process by inhibiting factor D or C5 could mitigate SARS-CoV-2–induced immunopathology.

Publication types

  • Comment

MeSH terms

  • Betacoronavirus
  • COVID-19
  • Complement Activation
  • Complement Factor D*
  • Complement Pathway, Alternative
  • Coronavirus Infections*
  • Humans
  • Pandemics*
  • Pneumonia, Viral*
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus

Substances

  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2
  • Complement Factor D